Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06544395
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-06
Brief Title:
Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal Respiratory and Neurological Conditions Due to Impaired Taste and Smell
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVID-19
Brief Summary:
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological respiratory and musculoskeletal pathologies derived from the consequences of Covid-19 It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelaeThe main question it aim to answer is
- Is non-invasive neuromodulation effective as a therapy in neurological respiratory and musculoskeletal pathologies derived from the consequences of Covid-19
Researchers will compare non-invasive neuromodulation to a placebo treatment with the machine turned off
Participants will
Be evaluated before starting treatment
Be evaluated 3 weeks after
Be evaluated at 5 weeks or 15 sessions or completion of treatment
Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment
- Is non-invasive neuromodulation effective as a therapy in neurological respiratory and musculoskeletal pathologies derived from the consequences of Covid-19
Researchers will compare non-invasive neuromodulation to a placebo treatment with the machine turned off
Participants will
Be evaluated before starting treatment
Be evaluated 3 weeks after
Be evaluated at 5 weeks or 15 sessions or completion of treatment
Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment
Detailed Description:
The waves of Sars-Cov-2 disease continue to be continuous and we are increasingly aware of the consequences it causes both in the respiratory system musculoskeletal system and in the central and peripheral nervous system
Likewise non-invasive neuromodulation acts with a pump of ions generating endogenous stimuli that modulate the central nervous system
The aim of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological respiratory and musculoskeletal pathologies derived from the consequences of Covid-19
To carry out this study pain was measured with the visual analogue scale It was also measured the joint amplitude a muscle assessment with the help of a strength dynamometer the patients independence with the Katz index and the functionality of the lower or upper limbs depending on the affected joint
Likewise non-invasive neuromodulation acts with a pump of ions generating endogenous stimuli that modulate the central nervous system
The aim of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological respiratory and musculoskeletal pathologies derived from the consequences of Covid-19
To carry out this study pain was measured with the visual analogue scale It was also measured the joint amplitude a muscle assessment with the help of a strength dynamometer the patients independence with the Katz index and the functionality of the lower or upper limbs depending on the affected joint
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None